• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

增强的病灶 Foxp3 表达和外周无反应性淋巴细胞表明调节性 T 细胞在印度晚发性皮肤利什曼病中起作用。

Enhanced lesional Foxp3 expression and peripheral anergic lymphocytes indicate a role for regulatory T cells in Indian post-kala-azar dermal leishmaniasis.

机构信息

Department of Pharmacology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India.

出版信息

J Invest Dermatol. 2010 Apr;130(4):1013-22. doi: 10.1038/jid.2009.393. Epub 2009 Dec 24.

DOI:10.1038/jid.2009.393
PMID:20032994
Abstract

Indian post-kala-azar dermal leishmaniasis (PKDL) is a low-frequency (5-10%) dermal sequela of visceral leishmaniasis (VL) caused by Leishmania donovani; importantly, affected individuals are speculated to be parasite reservoirs. Insight into its immunopathogenesis could translate into rational immunomodulatory therapeutic approaches against leishmaniases. In patients with PKDL (n=21), peripheral lymphocytes were analyzed for surface markers, intracellular cytokines, and lymphoproliferative responses using flow cytometry. In lesional tissue biopsies (n=12), expression of counter-regulatory cytokines (IFN-gamma and IL-10) and the T-regulatory transcription factor forkhead box protein 3 (Foxp3) was analyzed using reverse transcriptase-PCR, along with immunohistochemical detection (n=8) of CD3 and Foxp3 positivity. In patients with PKDL, circulating CD8(+)CD28(-) and antigen-induced IL-10(+)CD3(+) lymphocytes were increased and receded with treatment. CD8(+) lymphocytes showed impaired proliferative responses to L. donovani antigen (LDA) and phytohemagglutinin, which were reinstated after treatment. At presentation, the upregulated lesional IFN-gamma and IL-10 messenger RNA (mRNA), Foxp3 mRNA, and protein were curtailed after treatment. In Indian patients with PKDL, increased frequency of the CD8(+)CD28(-) phenotype, enhanced antigen-specific IL-10 production, and accompanying anergy of circulating lymphocytes suggest their regulatory nature. Furthermore, the concomitantly elevated lesional expression of Foxp3 suggests their possible recruitment into the lesional site, which would sustain disease pathology.

摘要

印度内脏利什曼病(VL)后皮肤利什曼病(PKDL)是一种低频率(5-10%)的皮肤后遗症,由杜氏利什曼原虫引起;重要的是,受影响的个体被推测为寄生虫储库。对其免疫发病机制的深入了解可以转化为针对利什曼病的合理免疫调节治疗方法。在 PKDL 患者(n=21)中,使用流式细胞术分析外周淋巴细胞的表面标志物、细胞内细胞因子和淋巴增殖反应。在病变组织活检(n=12)中,使用逆转录-PCR 分析了负调节细胞因子(IFN-γ和 IL-10)和 T 调节转录因子叉头框蛋白 3(Foxp3)的表达,并进行了 CD3 和 Foxp3 阳性的免疫组织化学检测(n=8)。在 PKDL 患者中,循环 CD8(+)CD28(-)和抗原诱导的 IL-10(+)CD3(+)淋巴细胞增加,并随治疗而消退。CD8(+)淋巴细胞对杜氏利什曼原虫抗原(LDA)和植物血凝素的增殖反应受损,治疗后恢复。在出现时,上调的病变 IFN-γ和 IL-10 信使 RNA(mRNA)、Foxp3 mRNA 和蛋白在治疗后被抑制。在印度 PKDL 患者中,CD8(+)CD28(-)表型的频率增加、增强的抗原特异性 IL-10 产生以及伴随的循环淋巴细胞的无能表明它们具有调节性质。此外,病变中 Foxp3 的同时升高表明它们可能被招募到病变部位,这将维持疾病病理学。

相似文献

1
Enhanced lesional Foxp3 expression and peripheral anergic lymphocytes indicate a role for regulatory T cells in Indian post-kala-azar dermal leishmaniasis.增强的病灶 Foxp3 表达和外周无反应性淋巴细胞表明调节性 T 细胞在印度晚发性皮肤利什曼病中起作用。
J Invest Dermatol. 2010 Apr;130(4):1013-22. doi: 10.1038/jid.2009.393. Epub 2009 Dec 24.
2
Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis.白细胞介素-10和IgG3水平升高是印度黑热病后皮肤利什曼病的特征。
J Infect Dis. 2008 Jun 15;197(12):1762-71. doi: 10.1086/588387.
3
Post-kala-azar dermal leishmaniasis--an overview.Post-kala-azar dermal leishmaniasis--an overview.
Int J Dermatol. 2010 Aug;49(8):921-31. doi: 10.1111/j.1365-4632.2010.04558.x.
4
Evaluation of cellular immunological responses in mono- and polymorphic clinical forms of post-kala-azar dermal leishmaniasis in India.印度黑热病后皮肤利什曼病单形和多形临床形式的细胞免疫反应评估。
Clin Exp Immunol. 2016 Jul;185(1):50-60. doi: 10.1111/cei.12787. Epub 2016 May 4.
5
Decreased Frequency and Secretion of CD26 Promotes Disease Progression in Indian Post Kala-azar Dermal Leishmaniasis.CD26频率和分泌减少促进印度黑热病后皮肤利什曼病的疾病进展。
J Clin Immunol. 2016 Jan;36(1):85-94. doi: 10.1007/s10875-015-0215-8. Epub 2015 Dec 7.
6
Foxp3 and IL-10 expression correlates with parasite burden in lesional tissues of post kala azar dermal leishmaniasis (PKDL) patients.Foxp3 和 IL-10 的表达与皮肤利什曼病(PKDL)患者皮损组织中的寄生虫负担相关。
PLoS Negl Trop Dis. 2011;5(5):e1171. doi: 10.1371/journal.pntd.0001171. Epub 2011 May 31.
7
IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.白蛉热和黑热病后皮肤利什曼病中白细胞介素-10和转化生长因子-β介导的易感性:两性霉素B在印度控制杜氏利什曼原虫感染中的意义
J Immunol. 2007 Oct 15;179(8):5592-603. doi: 10.4049/jimmunol.179.8.5592.
8
Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile.黑热病后皮肤利什曼病(PKDL)的免疫病理学:T细胞表型和细胞因子谱
J Pathol. 1999 Dec;189(4):615-22. doi: 10.1002/(SICI)1096-9896(199912)189:4<615::AID-PATH466>3.0.CO;2-Z.
9
Evaluation of serological markers to monitor the disease status of Indian post kala-azar dermal leishmaniasis.评估血清学标志物以监测印度内脏利什曼病皮肤后时期的疾病状态。
Trans R Soc Trop Med Hyg. 2012 Nov;106(11):668-76. doi: 10.1016/j.trstmh.2012.07.005. Epub 2012 Aug 21.
10
Interferon (IFN)-gamma , tumor necrosis factor-alpha , interleukin-6, and IFN-gamma receptor 1 are the major immunological determinants associated with post-kala azar dermal leishmaniasis.γ干扰素、肿瘤坏死因子-α、白细胞介素-6和γ干扰素受体1是与黑热病后皮肤利什曼病相关的主要免疫决定因素。
J Infect Dis. 2006 Oct 1;194(7):958-65. doi: 10.1086/506624. Epub 2006 Aug 23.

引用本文的文献

1
Post-kala-azar dermal leishmaniasis (PKDL) drug efficacy study landscape: A systematic scoping review of clinical trials and observational studies to assess the feasibility of establishing an individual participant-level data (IPD) platform.无鞭毛体利什曼病(PKDL)药物疗效研究现状:一项系统评价临床试验和观察性研究的范围界定,以评估建立个体参与者水平数据(IPD)平台的可行性。
PLoS Negl Trop Dis. 2024 Apr 16;18(4):e0011635. doi: 10.1371/journal.pntd.0011635. eCollection 2024 Apr.
2
Post kala-azar dermal leishmaniasis in the Indian sub-continent: challenges and strategies for elimination.印度次大陆的无黑热病皮肤利什曼病:消除的挑战与策略。
Front Immunol. 2023 Aug 11;14:1236952. doi: 10.3389/fimmu.2023.1236952. eCollection 2023.
3
IgG3 and IL10 are effective biomarkers for monitoring therapeutic effectiveness in Post Kala-Azar Dermal Leishmaniasis.IgG3 和 IL10 是监测 Post Kala-Azar Dermal Leishmaniasis 治疗效果的有效生物标志物。
PLoS Negl Trop Dis. 2021 Nov 10;15(11):e0009906. doi: 10.1371/journal.pntd.0009906. eCollection 2021 Nov.
4
Immune Responses in Post Kala-azar Dermal Leishmaniasis.黑热病后皮肤利什曼病中的免疫反应
Indian J Dermatol. 2020 Nov-Dec;65(6):452-460. doi: 10.4103/ijd.IJD_258_20.
5
Differential Regulation of miRNA Profiles of Human Cells Experimentally Infected by Isolated From Indian Visceral Leishmaniasis and Post-Kala-Azar Dermal Leishmaniasis.从印度内脏利什曼病和黑热病后皮肤利什曼病中分离出的[病原体名称未给出]实验感染的人类细胞miRNA谱的差异调控 。 (注:原文中“Isolated From Indian Visceral Leishmaniasis and Post-Kala-Azar Dermal Leishmaniasis.”前缺少具体的病原体等关键信息,导致译文不太完整准确)
Front Microbiol. 2020 Jul 31;11:1716. doi: 10.3389/fmicb.2020.01716. eCollection 2020.
6
Post kala-azar dermal leishmaniasis: A threat to elimination program.无鞭毛体利什曼原虫病皮肤后:消除规划的威胁。
PLoS Negl Trop Dis. 2020 Jul 2;14(7):e0008221. doi: 10.1371/journal.pntd.0008221. eCollection 2020 Jul.
7
In-situ immune profile of polymorphic vs. macular Indian Post Kala-azar dermal leishmaniasis.印度卵形与弥漫型皮肤利什曼病原位免疫特征。
Int J Parasitol Drugs Drug Resist. 2019 Dec;11:166-176. doi: 10.1016/j.ijpddr.2019.08.005. Epub 2019 Aug 22.
8
Impaired activation of lesional CD8 T-cells is associated with enhanced expression of Programmed Death-1 in Indian Post Kala-azar Dermal Leishmaniasis.印度内脏利什曼病皮肤利什曼病皮损中 CD8 T 细胞的活化受损与程序性死亡受体-1的表达增强有关。
Sci Rep. 2019 Jan 24;9(1):762. doi: 10.1038/s41598-018-37144-y.
9
Description of CD8 Regulatory T Lymphocytes and Their Specific Intervention in Graft-versus-Host and Infectious Diseases, Autoimmunity, and Cancer.CD8 调节性 T 淋巴细胞的描述及其在移植物抗宿主病和感染性疾病、自身免疫性疾病和癌症中的特异性干预作用。
J Immunol Res. 2018 Aug 5;2018:3758713. doi: 10.1155/2018/3758713. eCollection 2018.
10
Immune Checkpoint Targets for Host-Directed Therapy to Prevent and Treat Leishmaniasis.用于宿主导向疗法预防和治疗利什曼病的免疫检查点靶点
Front Immunol. 2017 Nov 8;8:1492. doi: 10.3389/fimmu.2017.01492. eCollection 2017.